Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Cancer Targeted Metallic Nanoparticle: Targeting Overview, Recent Advancement and Toxicity Concern

Author(s): Sohail Akhter, Mohammad Zaki Ahmad, Anjali Singh, Iqbal Ahmad, Mahfoozur Rahman, Mohammad Anwar, Gaurav Kumar Jain, Farhan Jalees Ahmad and Roop Krishen Khar

Volume 17, Issue 18, 2011

Page: [1834 - 1850] Pages: 17

DOI: 10.2174/138161211796391001

Price: $65

Abstract

The targeted delivery of theranostic agents to the cancer cells is one of the major challenges and an active field of research in the development of cancer chemotherapeutic approaches. Theranostic metallic nanoparticles (TMNPs) have garnered increasing attention in recent years as a novel tool for theranostic application such as imaging, diagnosis, and therapeutic delivery of active agents to tumour specific cells. This paper attempts to unveil the multidimensional theranostic aspects of multifunctional metallic nanoparticles (MNPs) including passive and active targeting (HER2, Folate, Angiogenesis etc.) as well as the RES escaping approach. Special attention is given to the theranostic application of MNPs in oncology. Patents issued by the US office in this nanotechnological arena are also included emphasising the importance of MNPs in current cancer treatment/imaging research scenario. Keeping in mind the blooming research in clinical application directed nanotechnology; toxicity concerns related with MNPs are. also discussed, in element.

Keywords: Metallic nanoparticles (MNPs), Active and passive targeting, Patents, Theranostic application, Quantum dots, Toxicity assessment, Toxicity, Metallic nanoparticles, Abraxan, Doxil, tumours, electrostatic, diagnostic, theranostic, oncological, mononuclear, phagocyte, zeta potential


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy